Physician profile
Arash A Horizon
NPI 1881694131
$1,467.83
in general payments reported to CMS, 2019-2025
12 companies · $46.41 in 2025
The $46.41 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $246 · 2021: $22.64 · 2022: $120 · 2023: $139 · 2024: $37.87 · 2025: $46.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $222.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $369.44 | 2019-2025 | Krystexxa |
| Abbvie INC. | $335.29 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $224.58 | 2019-2020 | |
| Pfizer INC. | $145.11 | 2019-2020 | |
| Celgene Corporation | $111.87 | 2019 | |
| Lilly USA, LLC | $85.48 | 2019-2020 | |
| Horizon Therapeutics Plc | $75.35 | 2019-2022 | |
| Genentech USA, INC. | $60.53 | 2019-2020 | |
| Janssen Biotech, INC. | $25.31 | 2019 | |
| Depuy Synthes Sales INC. | $22.64 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.23 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arash Horizon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.